Evolus, Inc. (EOLS)
Automate Your Wheel Strategy on EOLS
With Tiblio's Option Bot, you can configure your own wheel strategy including EOLS - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol EOLS
- Rev/Share 4.3176
- Book/Share -0.1037
- PB -94.7155
- Debt/Equity -1.271
- CurrentRatio 2.3424
- ROIC -0.2485
- MktCap 633150392.0
- FreeCF/Share -0.3914
- PFCF -25.3931
- PE -11.1293
- Debt/Assets 0.0393
- DivYield 0
- ROE -9.3198
- Rating C
- Score 2
- Recommendation Sell
- P/E Score 1
- DCF Score 1
- P/B Score 1
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Initiation | EOLS | BTIG Research | -- | Buy | -- | $21 | April 17, 2025 |
News
Evolus, Inc. (EOLS) Reports Q1 Loss, Misses Revenue Estimates
Published: May 07, 2025 by: Zacks Investment Research
Sentiment: Negative
Evolus, Inc. (EOLS) came out with a quarterly loss of $0.18 per share versus the Zacks Consensus Estimate of a loss of $0.10. This compares to loss of $0.13 per share a year ago.
Read More
Evolus, Inc. (EOLS) Q1 2025 Earnings Call Transcript
Published: May 07, 2025 by: Seeking Alpha
Sentiment: Neutral
Evolus, Inc. (NASDAQ:EOLS ) Q1 2025 Earnings Conference Call May 7, 2025 4:30 PM ET Company Participants Nareg Sagherian - VP, Head of Global IR and Corporate Communications David Moatazedi - President and CEO Sandra Beaver - CFO Conference Call Participants Annabel Samimy - Stifel Marc Goodman - Leerink Partners Navann Ty - BNP Paribas Serge Belanger - Needham Doug Tsao - H.C. Wainwright Sam Eiber - BTIG Operator Good afternoon, everyone.
Read More
Evolus, Inc. (EOLS) Q4 Earnings and Revenues Lag Estimates
Published: March 04, 2025 by: Zacks Investment Research
Sentiment: Negative
Evolus, Inc. (EOLS) came out with quarterly earnings of $0.01 per share, missing the Zacks Consensus Estimate of $0.06 per share. This compares to loss of $0.14 per share a year ago.
Read More
Evolus (EOLS) Moves 5.5% Higher: Will This Strength Last?
Published: February 14, 2025 by: Zacks Investment Research
Sentiment: Positive
Evolus (EOLS) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Read More
US FDA approves Evolus' anti-wrinkle gels
Published: February 13, 2025 by: Reuters
Sentiment: Positive
Evolus said on Thursday the U.S. Food and Drug Administration has approved its two new anti-wrinkle injectable gels, expanding the company's product portfolio beyond its cosmetic injection Jeuveau.
Read More
Evolus Announces FDA Approval of Evolysse™ Form and Evolysse™ Smooth Injectable Hyaluronic Acid Gels
Published: February 13, 2025 by: Business Wire
Sentiment: Neutral
NEWPORT BEACH, Calif.--(BUSINESS WIRE)--Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio, today announced that the U.S. Food and Drug Administration (FDA) has approved Evolysse™ Form and Evolysse™ Smooth injectable hyaluronic acid (HA) gels, the first two products in the Evolysse™ collection. These approvals mark Evolus' entry into the U.S. HA dermal filler market and solidifies the company's position as a multi-product innovator in aesth.
Read More
About Evolus, Inc. (EOLS)
- IPO Date 2018-02-08
- Website https://www.evolus.com
- Industry Drug Manufacturers - Specialty & Generic
- CEO Mr. David Moatazedi
- Employees 372